Literature DB >> 10603389

In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors.

T E Pickett1, M F Pasetti, J E Galen, M B Sztein, M M Levine.   

Abstract

Attenuated Salmonella enterica serovar Typhi live vector vaccine strains are highly immunogenic in mice following intranasal but not orogastric inoculation. To elucidate the relationship between organs within which vaccine organisms are found and the induction of specific serum immunoglobulin G (IgG) antibodies, we examined the in vivo distribution of serovar Typhi vaccine strain CVD 908-htrA following intranasal administration. Vaccine organisms were cultured from the nasal lymphoid tissue (NALT), lungs, and Peyer's patches 2 min after intranasal inoculation. Vaccine organisms persisted longer in NALT than in other organs. By decreasing the volume of intranasal inoculum containing 10(9) CFU (from a single 30- or 10-microl dose to four 2.5-microl doses given over the course of 1 h), we were able to significantly reduce the number of vaccine organisms isolated from the lungs (P < 0.05) without reducing the number of vaccine organisms in NALT. Reducing the number of vaccine organisms in the lungs resulted in a significant decrease in the serum tetanus antitoxin response elicited by CVD 908-htrA expressing tetanus toxin fragment C under the control of the redox-responsive nir15 promoter. In contrast, a similar construct expressing tetanus toxin fragment C under control of the constitutive lpp promoter stimulated a strong serum IgG tetanus antitoxin response with both inoculation regimens. The data suggest that following intranasal inoculation, NALT is a sufficient inductive site for elicitation of an immune response against both the live vector and heterologous antigen and, as occurs following oral inoculation of humans, attenuated serovar Typhi vaccine organisms elicit serum IgG responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10603389      PMCID: PMC97122          DOI: 10.1128/IAI.68.1.205-213.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA.

Authors:  N Orr; J E Galen; M M Levine
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

2.  Expression of host resistance to Salmonella typhi and Salmonella typhimurium: bacterial survival within macrophages of murine and human origin.

Authors:  I R Vladoianu; H R Chang; J C Pechère
Journal:  Microb Pathog       Date:  1990-02       Impact factor: 3.738

3.  High level heterologous expression in E. coli using the anaerobically-activated nirB promoter.

Authors:  M D Oxer; C M Bentley; J G Doyle; T C Peakman; I G Charles; A J Makoff
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

4.  Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines.

Authors:  S K Hoiseth; B A Stocker
Journal:  Nature       Date:  1981-05-21       Impact factor: 49.962

5.  Comparative morphometry of the nasal cavity in rats and mice.

Authors:  E A Gross; J A Swenberg; S Fields; J A Popp
Journal:  J Anat       Date:  1982-08       Impact factor: 2.610

6.  A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans.

Authors:  D M Hone; S R Attridge; B Forrest; R Morona; D Daniels; J T LaBrooy; R C Bartholomeusz; D J Shearman; J Hackett
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

7.  Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier.

Authors:  N F Fairweather; S N Chatfield; A J Makoff; R A Strugnell; J Bester; D J Maskell; G Dougan
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

8.  Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.

Authors:  C O Tacket; D M Hone; G A Losonsky; L Guers; R Edelman; M M Levine
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

9.  Innate resistance of mice to Salmonella typhi infection.

Authors:  A D O'Brien
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

10.  The route of enteric infection in normal mice.

Authors:  P B Carter; F M Collins
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

View more
  34 in total

1.  Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans.

Authors:  A K Turner; T D Terry; D A Sack; P Londoño-Arcila; M J Darsley
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.

Authors:  J Y Wang; M F Pasetti; F R Noriega; R J Anderson; S S Wasserman; J E Galen; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia.

Authors:  Derrick R Samuelson; Nicholas M de la Rua; Tysheena P Charles; Sanbao Ruan; Christopher M Taylor; Eugene E Blanchard; Meng Luo; Alistair J Ramsay; Judd E Shellito; David A Welsh
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

Review 4.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

5.  Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Authors:  Leslie W J Baillie; Ana L Rodriguez; Stephen Moore; Helen S Atkins; Chiguang Feng; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2008-09-19       Impact factor: 3.641

Review 6.  The microbiome and regulation of mucosal immunity.

Authors:  Andrew J McDermott; Gary B Huffnagle
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

7.  Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.

Authors:  Chee-Mun Fang; Jin Yuan Wang; Magaly Chinchilla; Myron M Levine; William C Blackwelder; James E Galen
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

8.  Role of antibiotics and fungal microbiota in driving pulmonary allergic responses.

Authors:  Mairi C Noverr; Rachael M Noggle; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Immunogenicity of a live recombinant Salmonella enterica serovar typhimurium vaccine expressing pspA in neonates and infant mice born from naive and immunized mothers.

Authors:  Huoying Shi; Shifeng Wang; Kenneth L Roland; Bronwyn M Gunn; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2010-01-06

10.  Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.

Authors:  Huoying Shi; Shifeng Wang; Roy Curtiss
Journal:  Clin Vaccine Immunol       Date:  2013-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.